Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that… Read more
Market Cap & Net Worth: Tanvex BioPharma Inc (6541)
Tanvex BioPharma Inc (TW:6541) has a market capitalization of $346.70 Million (NT$11.47 Billion) as of March 19, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #17851 globally and #777 in its home market, demonstrating a 2.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tanvex BioPharma Inc's stock price NT$43.35 by its total outstanding shares 264610367 (264.61 Million).
Tanvex BioPharma Inc Market Cap History: 2015 to 2026
Tanvex BioPharma Inc's market capitalization history from 2015 to 2026. Data shows change from $1.74 Billion to $346.70 Million (-8.18% CAGR).
Tanvex BioPharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tanvex BioPharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
15.04x
Tanvex BioPharma Inc's market cap is 15.04 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $296.34 Million | $300.00K | -$2.10 Billion | 987.80x | N/A |
| 2021 | $464.66 Million | $5.41 Million | -$1.54 Billion | 85.95x | N/A |
| 2022 | $280.72 Million | $22.40 Million | -$1.64 Billion | 12.53x | N/A |
| 2023 | $520.64 Million | $61.41 Million | -$2.14 Billion | 8.48x | N/A |
| 2024 | $521.44 Million | $34.68 Million | -$1.38 Billion | 15.04x | N/A |
Competitor Companies of 6541 by Market Capitalization
Companies near Tanvex BioPharma Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Tanvex BioPharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Tanvex BioPharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Tanvex BioPharma Inc's market cap moved from $1.74 Billion to $ 346.70 Million, with a yearly change of -8.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$346.70 Million | -21.18% |
| 2025 | NT$439.87 Million | -15.64% |
| 2024 | NT$521.44 Million | +0.15% |
| 2023 | NT$520.64 Million | +85.47% |
| 2022 | NT$280.72 Million | -39.59% |
| 2021 | NT$464.66 Million | +56.80% |
| 2020 | NT$296.34 Million | -14.70% |
| 2019 | NT$347.40 Million | -27.93% |
| 2018 | NT$482.02 Million | -16.68% |
| 2017 | NT$578.54 Million | -51.13% |
| 2016 | NT$1.18 Billion | -32.12% |
| 2015 | NT$1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Tanvex BioPharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $346.70 Million USD |
| MoneyControl | $346.70 Million USD |
| MarketWatch | $346.70 Million USD |
| marketcap.company | $346.70 Million USD |
| Reuters | $346.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.